Empowered Funds LLC Purchases New Stake in TransMedics Group, Inc. $TMDX

Key Points

• Empowered Funds LLC acquired 48,154 shares of TransMedics Group during the second quarter, valued at approximately $3.2 million. Institutional investors and hedge funds collectively own 99.67% of the company.
• Analyst sentiment is mixed, with six Buy, six Hold and one Sell rating. The consensus rating is Hold, with an average price target of $124.18.
• TransMedics reported quarterly revenue of $189.95 million, up 20.7% year over year and above estimates, but earnings per share of $0.44 missed the $0.50 consensus. Shares opened at $82.24, well below their 12-month high of $156.

Empowered Funds LLC acquired a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 48,154 shares of the company's stock, valued at approximately $3,198,000. Empowered Funds LLC owned about 0.14% of TransMedics Group as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Parallel Advisors LLC increased its stake in shares of TransMedics Group by 42.1% in the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company's stock worth $34,000 after acquiring an additional 83 shares during the last quarter. HighPoint Advisor Group LLC boosted its position in shares of TransMedics Group by 3.1% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,955 shares of the company's stock valued at $359,000 after acquiring an additional 88 shares during the last quarter. Crossmark Global Holdings Inc. grew its holdings in shares of TransMedics Group by 4.0% in the fourth quarter. Crossmark Global Holdings Inc. now owns 2,275 shares of the company's stock valued at $277,000 after purchasing an additional 88 shares during the period. Canada Pension Plan Investment Board grew its holdings in shares of TransMedics Group by 2.9% in the second quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company's stock valued at $482,000 after purchasing an additional 100 shares during the period. Finally, US Bancorp DE grew its holdings in shares of TransMedics Group by 24.2% in the third quarter. US Bancorp DE now owns 533 shares of the company's stock valued at $60,000 after purchasing an additional 104 shares during the period. Institutional investors and hedge funds own 99.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Wall Street Zen downgraded shares of TransMedics Group from a "hold" rating to a "sell" rating in a research note on Saturday, May 9th. Needham & Company LLC dropped their price target on shares of TransMedics Group from $142.00 to $106.00 and set a "buy" rating for the company in a research note on Monday, August 3rd. Canaccord Genuity Group restated a "buy" rating and set a $124.00 price target on shares of TransMedics Group in a report on Tuesday, June 30th. TD Cowen reaffirmed a "buy" rating and set a $120.00 price target on shares of TransMedics Group in a research report on Wednesday, July 1st. Finally, Oppenheimer cut TransMedics Group from an "outperform" rating to a "market perform" rating in a report on Wednesday, May 6th. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, TransMedics Group has a consensus rating of "Hold" and a consensus price target of $124.18.

TransMedics Group Stock Down 3.1%

Shares of NASDAQ:TMDX opened at $82.24 on Wednesday. The company has a market capitalization of $2.84 billion, a price-to-earnings ratio of 21.14 and a beta of 1.90. TransMedics Group, Inc. has a 12-month low of $60.10 and a 12-month high of $156.00. The business has a 50-day moving average price of $79.40 and a 200 day moving average price of $92.84. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.06). The company had revenue of $189.95 million during the quarter, compared to analyst estimates of $184.00 million. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The company's quarterly revenue was up 20.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.92 EPS. Sell-side analysts expect that TransMedics Group, Inc. will post 1.46 EPS for the current year.

Insider Activity

In other news, Director Thomas J. Gunderson sold 9,624 shares of the company's stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the transaction, the director directly owned 16,642 shares in the company, valued at approximately $1,249,148.52. This represents a 36.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source